Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

osphorylation of MET following administration of XL880. These decreases resulted in predicted downstream effects, including reduction of phosphorylated AKT levels and markedly increased tumor cell death. These effects were not observed in control samples of normal tissue obtained from the same patients. Pharmacokinetic analyses showed that peak and average concentrations over 28 days were higher with intermittent compared with daily dosing of XL880, reflecting the higher dose administered with the intermittent schedule, and the compound's long half life.

The data indicate that XL880 was generally well tolerated, and that the reported side effects were treatable and reversible. Dose limiting toxicities included hypertension, dehydration, hand-foot syndrome, tumor hemorrhage, and elevation of liver enzymes and lipase. Most of the common reported side effects are consistent with previously identified effects associated with inhibition of VEGF signaling, such as hypertension and proteinuria. Elevations in liver function tests also were observed and considered possibly related to XL880.

"We believe these results clearly demonstrate that XL880 simultaneously inhibits both MET and VEGFR2 in this clinical setting," said Michael M. Morrissey, Ph.D., president of research and development at Exelixis. "Inhibition of both MET and VEGFR2 abrogates two major mechanisms tumors use to survive in hypoxic conditions. The clinical data with XL880 suggest that dual MET/VEGFR2 inhibition has the potential to translate into meaningful anti-tumor activity in patients with advanced cancer."

(Back to top)

About XL880

XL880 has attractive pharmaceutical properties, with high solubility and oral bioavailability. In preclinical studies, XL880 inhibited its targets with nanomolar potency, and retained potent activity against mutationally activated forms of MET found in hereditary papillary renal cell carcinomas. The compound also demonstrated dose-dependent tu
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:12/16/2009)... Belgium, December 16 , ... Program With Microplasmin Recruits a Total of ... ThromboGenics NV (Euronext Brussels: ... and development of innovative treatments for eye,disease, ... it has completed,the enrolment of the second ...
(Date:12/15/2009)... Immucor, Inc. (Nasdaq: BLUD ), a global leader ... industry, today announced that it will release its fiscal ... after the market close. The Company will host a ... a.m. (Eastern Time) to discuss the results. ... call by dialing 1-888-324-9321 (Passcode: BLUD). Investors can also ...
(Date:12/15/2009)... DAYTON, Ohio, Dec. 15 Robbins & Myers, ... it will release results for its fiscal 2010 first ... on Wednesday, January 6, 2010. A live ... at 2:30 p.m., ET. Peter C. Wallace, ... Vice President and Chief Financial Officer, will be discussing ...
Breaking Medicine Technology:ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4Study IDs benefit of donor SCT for adults with acute myeloid leukemia 48388 1Study IDs benefit of donor SCT for adults with acute myeloid leukemia 48388 2Biologist discovers pink winged moth in Chiracahua Mountains 8779 1Biologist discovers pink winged moth in Chiracahua Mountains 8779 2Pelosi Statement on Release of Draft Health Reform Outline 48382 1
(Date:12/16/2009)... half, but use in humans is still far off , , ... nature, researchers have built and tested synthetic versions of the ... other cases where blood just won,t stop flowing. , "We ... in degradable stitches, which dissolve in the body," said Erin ... Reserve University, and lead author of a report published ...
(Date:12/16/2009)... for use, expert says, , , WEDNESDAY, Dec. 16 (HealthDay ... less likely to die when they receive an implantable ... included 4,685 people, ages 65 to 85, who were ... fraction (a measure of the heart,s pumping ability) of ... those who were treated with standard medication and an ...
(Date:12/16/2009)... -- Medical travel facilitator Companion Global Healthcare Inc. ... into its network of international hospitals that treat ... at mainland U.S. facilities. ,, The announcement means ... and preferred pricing for its individual clients and ... HIMA San Pablo Bayamon or HIMA San Pablo ...
(Date:12/16/2009)... -- Quantros, Inc., a leading provider of safety ... the healthcare industry, announces the creation of a ... software industry veteran Michael Tulloch, MBA, as Director ... the company,s new Marlborough, MA office. ,, "The ... explains Tulloch. "Quantros has been developing software for ...
(Date:12/16/2009)... families of sick and dying hospitalized children ask their ... do pediatricians respond to such personal requests? While increasing ... some patients and families cope with serious illness, a ... families and patients who raise the issue of prayer, ... of Southern Medical Journal , Brandeis and Rice ...
Breaking Medicine News(10 mins):Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:Implanted Defibrillator Might Extend Life 2Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2Health News:Safety and Quality Software Developer Quantros, Inc. Launches Healthcare IT Consulting Division 2Health News:Prayer on the hospital floor 2
... importance of awareness and education of ... ... an effort to raise money,for The Kidney TRUST(TM) -- a non-profit ... DaVita Inc., the nation,s,largest independent provider of kidney care, announced today ...
... Week Nov. 9-15, DENVER, Nov. 10 Students ... country can bring their beloved teddy,bears and other tattered ... button and bandage them today, teaching students a unique,lesson ... of the Association of the Perioperative Registered Nurses (AORN),Perioperative ...
... MTV GLOBALLY PREMIERES ORIGINAL HIV / AIDS PROGRAMMING ... DIARY OF KELLY ROWLAND, It,s about education. ... N.Y., Nov. 10 To mark 10 years ... MTV Staying Alive,has produced an enlightening documentary starring ...
... human genome project coupled with phenomenal growth in large-scale applications such ... well as highly specialized laboratory equipment. Global Pipettes and Pipettors market ... ... San Jose, CA (PRWEB) November 10, 2008 -- Pipettes and ...
... University Cites Nursing Shortage and High Demand for Nursing School Graduates with ... ... Board of Directors at the University of St. Thomas in Houston recently ... shortage of nurses., , , , ,The St. Thomas Nursing School operated ...
... the past decade with a significant increase in newer technologies, ... track imaging patterns in a managed care setting over a ... the November/December 2008 issue of the journal Health Affairs ... medical technology boom, the biggest driver of increasing healthcare costs. ...
Other Medicine News:Health News:Tour DaVita Raises More Than $400K for Kidney Disease Awareness 2Health News:Tour DaVita Raises More Than $400K for Kidney Disease Awareness 3Health News:Teddy Bear Hospital Helps Ease Kids' Anxieties About Surgery 2Health News:MTV's Staying Alive Marks Ten Years of Empowering Young People in Their Fight against HIV and AIDS 2Health News:MTV's Staying Alive Marks Ten Years of Empowering Young People in Their Fight against HIV and AIDS 3Health News:MTV's Staying Alive Marks Ten Years of Empowering Young People in Their Fight against HIV and AIDS 4Health News:MTV's Staying Alive Marks Ten Years of Empowering Young People in Their Fight against HIV and AIDS 5Health News:MTV's Staying Alive Marks Ten Years of Empowering Young People in Their Fight against HIV and AIDS 6Health News:Global Pipettes and Pipettors Market to Reach $996.2 Million by 2012, According to New Report by Global Industry Analysts, Inc. 2Health News:Global Pipettes and Pipettors Market to Reach $996.2 Million by 2012, According to New Report by Global Industry Analysts, Inc. 3Health News:University of St. Thomas Houston to Reopen Nursing School 2Health News:Study finds rise in rate of diagnostic imaging in managed care 2Health News:Study finds rise in rate of diagnostic imaging in managed care 3
The Clinac 2300 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
The Clinac 6EX accelerator is a cost-effective choice. Configured for the latest treatment techniques, the Clinac 6EX has the tightest mechanical and dosimetric specifications for any single-energy m...
Based on the clinically proven ACS MULTI-LINK Stent, ULTRA is a coronary stent system specifically designed for use in larger vessels. This innovative system utilizes a unique stent pattern to give y...
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Medicine Products: